Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Xuanxin Yang und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), Wenzhou Medical University,…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatocytes, Receptor, Fibroblast Growth Factor, Type 2, Fibroblast Growth Factor 10. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project for Innovative Drug Research and Development, National Natural Science Foundation of China, Xinjiang Safflower Industry Development Fund.
Abstract (Originalsprache)
Background
Metabolic dysfunction–associated steatotic liver disease (MASLD) and advanced fibrotic stages are significant contributors to cirrhosis and liver‐related mortality, yet no therapies directly target fibrosis in the later stages of the disease. Fibroblast growth factor 10 (FGF10) facilitates epithelial repair, yet its function and epithelial receptor requirements in chronic liver fibrogenesis are unclear.
Methods
We quantified hepatic FGF10 and fibroblast growth factor receptor 2 (FGFR2) expression across fibrosis stages in biopsies from patients with MASLD and mouse models. We then augmented hepatic FGF10 using adeno‐associated virus‐mediated liver expression or subcutaneous recombinant human FGF10 in carbon tetrachloride (CCl 4 ) and high‐fat diet plus CCl 4 ‐induced advanced fibrosis. Histology, immunohistochemistry, biochemistry, RNA sequencing and primary hepatocytes and hepatic stellate cells (HSCs) assays were used to assess the therapeutic effects and underlying mechanisms.
Results
Hepatic FGF10 and FGFR2 protein expression were significantly reduced at advanced disease stages. Restoring FGF10 led to regression‐associated remodelling of established bridging fibrosis, a decrease in inflammatory cytokines and a reduction in hepatocyte apoptosis, even with continued CCl 4 exposure, indicating histologic regression rather than slowed progression. These therapeutic effects required hepatocyte FGFR2, as hepatocyte‐specific FGFR2 deletion abolished protection and the associated transcriptional reprogramming of matrix and cytokine networks. In primary hepatocytes, FGF10 activated FGFR2–FGFR substrate 2α (FRS2α) signalling, increased inhibitory phosphorylation of glycogen synthase kinase 3β at Ser9 and suppressed nuclear factor kappa B, thereby lowering transforming growth factor β1 and other cytokines and indirectly limiting HSC activation. The efficacy extended to a high‐fat diet plus CCl 4 model of steatohepatitis.
Conclusions
These findings elucidate a hepatocyte‐centric FGF10–FGFR2 axis functioning as an epithelial regulator of inflammation and fibrogenesis. Hepatocyte‐targeted reinforcement of FGFR2 signalling, alone or combined with metabolic therapies, represents a translational strategy to reprogram the fibrotic niche and facilitate fibrosis regression‐associated architectural remodelling in advanced liver fibrosis. Key points Hepatic FGF10 and FGFR2 decline consistently with fibrosis stage in patient liver biopsies and complementary mouse models. Restoring FGF10 through AAV‐Fgf10 or recombinant FGF10 reduces hepatocyte apoptosis, inflammation and extracellular matrix deposition. Hepatocyte FGFR2 is required for FGF10‐mediated antifibrotic effects and drives transcriptional reprogramming that limits fibrogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), Wenzhou Medical University, Wenzhou, China.
- Institute for Safflower Industry Research of Shihezi University/Pharmacy College of Shihezi University/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi, China.
- MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
ORCID-Profile: Xuanxin Yang, Minghua Zheng, Xiaojie Wang
Förderung
- National Science and Technology Major Project for Innovative Drug Research and Development
- National Natural Science Foundation of China
- Xinjiang Safflower Industry Development Fund
Zitieren
APA
Yang, X., Dong, Q., Ma, J., Yan, Y., Peng, S., Wu, Q., Wang, H., Zhang, T., Zhang, P., Jiang, Z., Lu, C., Li, L., You, X., Xu, Y., Banda, J., Mu, Z., Zheng, M., Li, X., Hui, Q., …, & Wang, X. (2026). Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70675
Vancouver
Yang X, Dong Q, Ma J, Yan Y, Peng S, Wu Q, et al. Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70675
BibTeX
@article{Yang2026,
author = {Yang, Xuanxin and Dong, Qingqing and Ma, Jiaying and Yan, Yawei and Peng, Shuangyan and Wu, Qiqi and Wang, Huan and Zhang, Tingting and Zhang, Panyu and Jiang, Zelong and Lu, Chao and Li, Le and You, Xinyi and Xu, Yuandong and Banda, Joshua and Mu, Zhixiang and Zheng, Minghua and Li, Xiaokun and Hui, Qi and Yu, Bingjie and Wang, Xiaojie},
title = {Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70675}
}
EUVIMED